|
Orthologous residues
|
|
Jun (human): S63‑p, Jun (mouse): S63‑p, Jun (rat): S63‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
MEF (fibroblast), RAW 264 (macrophage)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
ERK1 (mouse)
|
pharmacological inhibitor of upstream enzyme, phospho-antibody, pharmacological activator of upstream enzyme
|
|
|
KINASE
|
JNK1 (mouse)
|
pharmacological inhibitor of upstream enzyme, phospho-antibody, genetic knockout/knockin of upstream enzyme, pharmacological activator of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
LPS
|
|
|
|
increase
|
|
|
PD184352, SB203580
|
LPS
|
|
|
augment treatment-induced increase
|
10-15% increase
|
|
TNF
|
|
|
|
increase
|
|
|
anisomycin
|
|
|
|
increase
|
|
|
phorbol ester
|
|
|
|
increase
|
|
|
PD184352
|
phorbol ester
|
|
|
inhibit treatment-induced increase
|
|
|
EGF
|
|
|
|
increase
|
|
|
PD184352
|
EGF
|
|
|
inhibit treatment-induced increase
|
|
|